Her-2 targeted therapy: beyond breast cancer and trastuzumab (Q36409209)

14 August 2017

1 reference

title

Her-2 targeted therapy: beyond breast cancer and trastuzumab (English)

1 reference

14 August 2017

1

Keith T Flaherty

1 reference

14 August 2017

2

Marcia S Brose

1 reference

14 August 2017

publication date

1 March 2006

1 reference

14 August 2017

published in

Current Oncology Reports

1 reference

14 August 2017

volume

8

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

90-95

1 reference

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor

14 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-006-0042-4

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

21 January 2018

1 reference

12 December 2020

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

1 reference

12 December 2020

Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer

1 reference

12 December 2020

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

1 reference

12 December 2020

Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?

1 reference

12 December 2020

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

12 December 2020

Dysregulation of cellular signaling by HER2/neu in breast cancer

1 reference

12 December 2020

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpres

1 reference

12 December 2020

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

1 reference

12 December 2020

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

1 reference

12 December 2020

Co-Expression of ErbB-Family Members in Human Breast Cancer: Her-2/neu is the Preferred Dimerization Candidate in Nodal-positive Tumors

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.

1 reference

12 December 2020

Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues

1 reference

12 December 2020

Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells

1 reference

12 December 2020

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

1 reference

12 December 2020

Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity

1 reference

12 December 2020

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

1 reference

12 December 2020

Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.

1 reference

12 December 2020

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

1 reference

12 December 2020

Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer

1 reference

12 December 2020

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

12 December 2020

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

1 reference

12 December 2020

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

12 December 2020

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

1 reference

12 December 2020

Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing

1 reference

12 December 2020

Trastuzumab and chemotherapeutics: drug interactions and synergies.

1 reference

12 December 2020

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

1 reference

12 December 2020

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

1 reference

12 December 2020

10.1007/S11912-006-0042-4

Identifiers

DOI

1 reference

release_qim3gffup5bnjinmwp5u4opmyi

14 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qim3gffup5bnjinmwp5u4opmyi

24 November 2022

mapped directly with Wikidata item

1 reference